Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Mesenchymal stromal cells in cancer: A review of their immunomodulatory functions and dual effects on tumor progression.

Galland S, Stamenkovic I.

J Pathol. 2019 Oct 14. doi: 10.1002/path.5357. [Epub ahead of print] Review.

PMID:
31608444
2.

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.

Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, Dewitt J, Gritsch S, Perez EM, Gonzalez Castro LN, Lan X, Druck N, Rodman C, Dionne D, Kaplan A, Bertalan MS, Small J, Pelton K, Becker S, Bonal D, Nguyen QD, Servis RL, Fung JM, Mylvaganam R, Mayr L, Gojo J, Haberler C, Geyeregger R, Czech T, Slavc I, Nahed BV, Curry WT, Carter BS, Wakimoto H, Brastianos PK, Batchelor TT, Stemmer-Rachamimov A, Martinez-Lage M, Frosch MP, Stamenkovic I, Riggi N, Rheinbay E, Monje M, Rozenblatt-Rosen O, Cahill DP, Patel AP, Hunter T, Verma IM, Ligon KL, Louis DN, Regev A, Bernstein BE, Tirosh I, Suvà ML.

Cell. 2019 Aug 8;178(4):835-849.e21. doi: 10.1016/j.cell.2019.06.024. Epub 2019 Jul 18.

PMID:
31327527
3.

Synovial sarcoma: when epigenetic changes dictate tumour development.

Riggi N, Cironi L, Stamenkovic I.

Swiss Med Wkly. 2018 Dec 2;148:w14667. doi: 10.4414/smw.2018.14667. eCollection 2018 Nov 19. Review.

4.

Epigenome editing of microsatellite repeats defines tumor-specific enhancer functions and dependencies.

Boulay G, Volorio A, Iyer S, Broye LC, Stamenkovic I, Riggi N, Rivera MN.

Genes Dev. 2018 Aug 1;32(15-16):1008-1019. doi: 10.1101/gad.315192.118. Epub 2018 Jul 24.

5.

Reciprocal modulation of mesenchymal stem cells and tumor cells promotes lung cancer metastasis.

Fregni G, Quinodoz M, Möller E, Vuille J, Galland S, Fusco C, Martin P, Letovanec I, Provero P, Rivolta C, Riggi N, Stamenkovic I.

EBioMedicine. 2018 Mar;29:128-145. doi: 10.1016/j.ebiom.2018.02.017. Epub 2018 Feb 23.

6.

Cancer Metastasis: A Reappraisal of Its Underlying Mechanisms and Their Relevance to Treatment.

Riggi N, Aguet M, Stamenkovic I.

Annu Rev Pathol. 2018 Jan 24;13:117-140. doi: 10.1146/annurev-pathol-020117-044127. Epub 2017 Oct 25. Review.

PMID:
29068753
7.

Tumor-Derived Mesenchymal Stem Cells Use Distinct Mechanisms to Block the Activity of Natural Killer Cell Subsets.

Galland S, Vuille J, Martin P, Letovanec I, Caignard A, Fregni G, Stamenkovic I.

Cell Rep. 2017 Sep 19;20(12):2891-2905. doi: 10.1016/j.celrep.2017.08.089.

8.

Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain.

Boulay G, Sandoval GJ, Riggi N, Iyer S, Buisson R, Naigles B, Awad ME, Rengarajan S, Volorio A, McBride MJ, Broye LC, Zou L, Stamenkovic I, Kadoch C, Rivera MN.

Cell. 2017 Sep 21;171(1):163-178.e19. doi: 10.1016/j.cell.2017.07.036. Epub 2017 Aug 24.

9.

IMPs: an RNA-binding protein family that provides a link between stem cell maintenance in normal development and cancer.

Degrauwe N, Suvà ML, Janiszewska M, Riggi N, Stamenkovic I.

Genes Dev. 2016 Nov 15;30(22):2459-2474. Review.

10.

The RNA Binding Protein IMP2 Preserves Glioblastoma Stem Cells by Preventing let-7 Target Gene Silencing.

Degrauwe N, Schlumpf TB, Janiszewska M, Martin P, Cauderay A, Provero P, Riggi N, Suvà ML, Paro R, Stamenkovic I.

Cell Rep. 2016 May 24;15(8):1634-47. doi: 10.1016/j.celrep.2016.04.086. Epub 2016 May 12.

11.

The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma.

Cironi L, Petricevic T, Fernandes Vieira V, Provero P, Fusco C, Cornaz S, Fregni G, Letovanec I, Aguet M, Stamenkovic I.

Sci Rep. 2016 Feb 24;6:22113. doi: 10.1038/srep22113.

13.

EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma.

Riggi N, Knoechel B, Gillespie SM, Rheinbay E, Boulay G, Suvà ML, Rossetti NE, Boonseng WE, Oksuz O, Cook EB, Formey A, Patel A, Gymrek M, Thapar V, Deshpande V, Ting DT, Hornicek FJ, Nielsen GP, Stamenkovic I, Aryee MJ, Bernstein BE, Rivera MN.

Cancer Cell. 2014 Nov 10;26(5):668-681. doi: 10.1016/j.ccell.2014.10.004. Epub 2014 Oct 30.

14.

Targeting cancer stem-like cells as an approach to defeating cellular heterogeneity in Ewing sarcoma.

Cornaz-Buros S, Riggi N, DeVito C, Sarre A, Letovanec I, Provero P, Stamenkovic I.

Cancer Res. 2014 Nov 15;74(22):6610-22. doi: 10.1158/0008-5472.CAN-14-1106. Epub 2014 Sep 26.

15.

Chaotropic agents in liquid chromatographic method development for the simultaneous analysis of levodopa, carbidopa, entacapone and their impurities.

Vemić A, Jančić Stojanović B, Stamenković I, Malenović A.

J Pharm Biomed Anal. 2013 Apr 15;77:9-15. doi: 10.1016/j.jpba.2013.01.007. Epub 2013 Jan 8.

PMID:
23354116
16.

Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells.

Janiszewska M, Suvà ML, Riggi N, Houtkooper RH, Auwerx J, Clément-Schatlo V, Radovanovic I, Rheinbay E, Provero P, Stamenkovic I.

Genes Dev. 2012 Sep 1;26(17):1926-44. doi: 10.1101/gad.188292.112. Epub 2012 Aug 16.

17.

A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma.

De Vito C, Riggi N, Cornaz S, Suvà ML, Baumer K, Provero P, Stamenkovic I.

Cancer Cell. 2012 Jun 12;21(6):807-21. doi: 10.1016/j.ccr.2012.04.023.

18.

Systematic identification of genomic markers of drug sensitivity in cancer cells.

Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, Zhang T, O'Brien P, Boisvert JL, Price S, Hur W, Yang W, Deng X, Butler A, Choi HG, Chang JW, Baselga J, Stamenkovic I, Engelman JA, Sharma SV, Delattre O, Saez-Rodriguez J, Gray NS, Settleman J, Futreal PA, Haber DA, Stratton MR, Ramaswamy S, McDermott U, Benes CH.

Nature. 2012 Mar 28;483(7391):570-5. doi: 10.1038/nature11005.

19.

Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development.

De Vito C, Riggi N, Suvà ML, Janiszewska M, Horlbeck J, Baumer K, Provero P, Stamenkovic I.

PLoS One. 2011;6(8):e23592. doi: 10.1371/journal.pone.0023592. Epub 2011 Aug 10.

20.

Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation.

Mauti LA, Le Bitoux MA, Baumer K, Stehle JC, Golshayan D, Provero P, Stamenkovic I.

J Clin Invest. 2011 Jul;121(7):2794-807. doi: 10.1172/JCI41936. Epub 2011 Jun 6.

21.

Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer.

Planche A, Bacac M, Provero P, Fusco C, Delorenzi M, Stehle JC, Stamenkovic I.

PLoS One. 2011;6(5):e18640. doi: 10.1371/journal.pone.0018640. Epub 2011 May 18.

22.

The cancer stem cell paradigm in Ewing's sarcoma: what can we learn about these rare cells from a rare tumor?

Riggi N, Suvà ML, Stamenkovic I.

Expert Rev Anticancer Ther. 2011 Feb;11(2):143-5. doi: 10.1586/era.10.235. No abstract available.

PMID:
21342030
23.

Securin and separase modulate membrane traffic by affecting endosomal acidification.

Bacac M, Fusco C, Planche A, Santodomingo J, Demaurex N, Leemann-Zakaryan R, Provero P, Stamenkovic I.

Traffic. 2011 May;12(5):615-26. doi: 10.1111/j.1600-0854.2011.01169.x. Epub 2011 Feb 25.

24.

Synergistic effect of hyaluronate fragments in retinaldehyde-induced skin hyperplasia which is a Cd44-dependent phenomenon.

Barnes L, Tran C, Sorg O, Hotz R, Grand D, Carraux P, Didierjean L, Stamenkovic I, Saurat JH, Kaya G.

PLoS One. 2010 Dec 16;5(12):e14372. doi: 10.1371/journal.pone.0014372.

25.

Transportin regulates nuclear import of CD44.

Janiszewska M, De Vito C, Le Bitoux MA, Fusco C, Stamenkovic I.

J Biol Chem. 2010 Oct 1;285(40):30548-57. doi: 10.1074/jbc.M109.075838. Epub 2010 Jul 27.

26.

[Synchronous colorectal adenomas].

Radovanović-Dinić B, Nagorni A, Stamenković I, Zlatic A.

Srp Arh Celok Lek. 2010 May-Jun;138(5-6):309-14. Serbian.

28.

EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells.

Riggi N, Suvà ML, De Vito C, Provero P, Stehle JC, Baumer K, Cironi L, Janiszewska M, Petricevic T, Suvà D, Tercier S, Joseph JM, Guillou L, Stamenkovic I.

Genes Dev. 2010 May;24(9):916-32. doi: 10.1101/gad.1899710. Epub 2010 Apr 9.

29.

CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma.

Xu Y, Stamenkovic I, Yu Q.

Cancer Res. 2010 Mar 15;70(6):2455-64. doi: 10.1158/0008-5472.CAN-09-2505. Epub 2010 Mar 2.

30.

Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1.

Cironi L, Provero P, Riggi N, Janiszewska M, Suva D, Suva ML, Kindler V, Stamenkovic I.

PLoS One. 2009 Nov 19;4(11):e7904. doi: 10.1371/journal.pone.0007904.

31.

EZH2 is essential for glioblastoma cancer stem cell maintenance.

Suvà ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, Marquez VE, Clément V, Stamenkovic I.

Cancer Res. 2009 Dec 15;69(24):9211-8. doi: 10.1158/0008-5472.CAN-09-1622.

32.

[Role of mucinohistochemical analysis in verification of malignant potential of colorectal adenoma].

Radovanović-Dinić B, Katić V, Nagorni A, Stamenković I.

Vojnosanit Pregl. 2009 Aug;66(8):623-8. Serbian.

PMID:
19780416
33.

Ewing's sarcoma origin: from duel to duality.

Riggi N, Suva ML, Stamenkovic I.

Expert Rev Anticancer Ther. 2009 Aug;9(8):1025-30. doi: 10.1586/era.09.81. No abstract available.

PMID:
19671021
34.

Malarial hemozoin is a Nalp3 inflammasome activating danger signal.

Dostert C, Guarda G, Romero JF, Menu P, Gross O, Tardivel A, Suva ML, Stehle JC, Kopf M, Stamenkovic I, Corradin G, Tschopp J.

PLoS One. 2009 Aug 4;4(8):e6510. doi: 10.1371/journal.pone.0006510.

35.

Chromosomal number aberrations and transformation in adult mouse retinal stem cells in vitro.

Djojosubroto M, Bollotte F, Wirapati P, Radtke F, Stamenkovic I, Arsenijevic Y.

Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5975-87. doi: 10.1167/iovs.08-3091. Epub 2009 Jul 23.

PMID:
19628750
36.

Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding.

Stamenkovic I, Yu Q.

J Invest Dermatol. 2009 Jun;129(6):1321-4. doi: 10.1038/jid.2009.13.

37.

An immunohistochemical study of Ki-67 in colorectal adenoma.

Radovanovic-Dinic B, Nagorni A, Katic V, Stamenkovic I, Zlatic A.

Med Arh. 2009;63(1):16-8.

PMID:
19419120
38.

Identification of cancer stem cells in Ewing's sarcoma.

Suvà ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, Suvà D, Clément V, Provero P, Cironi L, Osterheld MC, Guillou L, Stamenkovic I.

Cancer Res. 2009 Mar 1;69(5):1776-81. doi: 10.1158/0008-5472.CAN-08-2242. Epub 2009 Feb 10.

39.

Tumor-host interactions: the role of inflammation.

Le Bitoux MA, Stamenkovic I.

Histochem Cell Biol. 2008 Dec;130(6):1079-90. doi: 10.1007/s00418-008-0527-3. Epub 2008 Oct 25. Review.

PMID:
18953558
40.

IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells.

Cironi L, Riggi N, Provero P, Wolf N, Suvà ML, Suvà D, Kindler V, Stamenkovic I.

PLoS One. 2008 Jul 9;3(7):e2634. doi: 10.1371/journal.pone.0002634.

41.

EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.

Riggi N, Suvà ML, Suvà D, Cironi L, Provero P, Tercier S, Joseph JM, Stehle JC, Baumer K, Kindler V, Stamenkovic I.

Cancer Res. 2008 Apr 1;68(7):2176-85. doi: 10.1158/0008-5472.CAN-07-1761.

42.

Metastatic cancer cell.

Bacac M, Stamenkovic I.

Annu Rev Pathol. 2008;3:221-47. doi: 10.1146/annurev.pathmechdis.3.121806.151523. Review.

PMID:
18233952
43.

Sarcomas: genetics, signalling, and cellular origins. Part 2: TET-independent fusion proteins and receptor tyrosine kinase mutations.

Suvà ML, Cironi L, Riggi N, Stamenkovic I.

J Pathol. 2007 Oct;213(2):117-30. Review.

PMID:
17703479
44.

Sarcomas: genetics, signalling, and cellular origins. Part 1: The fellowship of TET.

Riggi N, Cironi L, Suvà ML, Stamenkovic I.

J Pathol. 2007 Sep;213(1):4-20. Review.

PMID:
17691072
45.

Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury.

Herrera MB, Bussolati B, Bruno S, Morando L, Mauriello-Romanazzi G, Sanavio F, Stamenkovic I, Biancone L, Camussi G.

Kidney Int. 2007 Aug;72(4):430-41. Epub 2007 May 16.

46.

The Biology of Ewing sarcoma.

Riggi N, Stamenkovic I.

Cancer Lett. 2007 Aug 28;254(1):1-10. Epub 2007 Jan 23. Review.

PMID:
17250957
47.

A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survival.

Bacac M, Provero P, Mayran N, Stehle JC, Fusco C, Stamenkovic I.

PLoS One. 2006 Dec 20;1:e32.

48.

Hyaluronate fragments reverse skin atrophy by a CD44-dependent mechanism.

Kaya G, Tran C, Sorg O, Hotz R, Grand D, Carraux P, Didierjean L, Stamenkovic I, Saurat JH.

PLoS Med. 2006 Dec;3(12):e493.

49.

Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin.

Bai Y, Liu YJ, Wang H, Xu Y, Stamenkovic I, Yu Q.

Oncogene. 2007 Feb 8;26(6):836-50. Epub 2006 Sep 4.

PMID:
16953231
50.

Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma.

Riggi N, Cironi L, Provero P, Suvà ML, Stehle JC, Baumer K, Guillou L, Stamenkovic I.

Cancer Res. 2006 Jul 15;66(14):7016-23.

Supplemental Content

Loading ...
Support Center